Formulating MSCA Budgets for Pharmacology, Toxicology & Pharmacy

1. Financial Alignment & Eligibility Standards

Securing research funding from Marie Skłodowska-Curie Actions requires meticulous adherence to both financial eligibility standards and administrative regulations. For projects in the domain of Pharmacology, Toxicology & Pharmacy, budgets must be constructed using realistic cost projections that are directly tied to the scientific methodology. Under-budgeting may jeopardise project execution, while over-budgeting or including ineligible costs often leads to immediate rejection during administrative screening.

For wet-lab research in Pharmacology, Toxicology & Pharmacy, budget formulations must prioritize chemical reagents, specialized assay consumables, and pay-per-use core facility fees. Investigators should avoid pooling general office supplies with specialized scientific consumables to prevent auditing flags during reviews of MSCA proposals.

Proposal teams must submit all budget items in the host institution's local currency, mapping them to the specific electronic submission environment (Funding & Tenders Portal). Every cost item must be justifiable as necessary, reasonable, and allocable to the project.

2. Direct vs. Indirect Cost Categorisation

A primary point of auditing compliance is the strict division between Direct Costs (expenses directly attributable to the execution of the research project) and Indirect Costs (institutional overheads, facility maintenance, and central administrative support).

Under active **MSCA** guidelines, overhead recovery is computed as a flat 25% addition to eligible direct costs. Investigators must omit subcontracting expenditures from the calculation base when formulating indirect recovery for **Pharmacology, Toxicology & Pharmacy** budgets.

For MSCA proposals, the indirect cost rate is structured as: Fully funded institutional unit costs. This rate must be applied correctly to the modified total direct cost base according to your institution's negotiated rate agreement or the flat rate set by the funder.

3. Step-by-Step Budget Justification Protocol

The budget justification (or budget narrative) is a critical component of the application reviewed by both financial auditors and peer reviewers. To draft a compliant narrative:

• Provide granular detail: Do not use lump sums. Break down personnel costs by calendar months or percentage of effort.
• Demonstrate direct linkage: For every cost, explain how it supports a specific task or objective in the research plan for Pharmacology, Toxicology & Pharmacy.
• Cite institutional policies: Reference verified institutional rates for fringe benefits, travel mileage, and indirect cost bases to validate your numbers.
• Verify supplier quotes: For major equipment purchases or specialized laboratory assays, upload or reference formal vendor quotes.

Pre-Award Framework, Cost Sharing & Post-Award Governance

Securing competitive funding from the Marie Skłodowska-Curie Actions (MSCA) for Pharmacology, Toxicology & Pharmacy research is grounded in professional grant development and institutional pre-award grant management structures. Proposals must respect the distinction of categorical grants vs block grants, where MSCA utilizes categorical grants bound by tight cost principles for Pharmacology, Toxicology & Pharmacy projects. When building the grant proposal timeline, the PI and co-principal investigator must ensure there is sufficient margin for institutional review and formal clearance of any cost sharing on grants. Effective project execution is governed by post-award grant management guidelines, which mandate establishing a robust subaward agreement research with co-investigators. Researchers must complete periodic effort certification research reports to satisfy MSCA auditing and ensure that interdisciplinary team science research runs smoothly.

4. Frequently Asked Questions